Overview of Nextum

Property	Description
Active ingredient	Cefoperazone (often combined with Sulbactam)
Form	Powder for injection (reconstituted to solution)
Pharmacological class	Third-generation Cephalosporin Antibiotic
Common purpose	Resolution of serious bacterial infections
Origin	Semisynthetic

Defining Nextum: An Injectable Third-Generation Antibiotic

Nextum is a semisynthetic, broad-spectrum antibiotic primarily utilized for the systemic resolution of serious bacterial infections. The medicine’s main active component, Cefoperazone, is formally classified as a third-generation cephalosporin, placing it in the larger family of beta-lactam antibiotics. This cephalosporin class is clinically recognized for its broad reach across various pathogens and its enhanced stability against certain bacterial enzymes.

Cefoperazone is derived from a natural compound but chemically modified, granting it semisynthetic status. Its third-generation status ensures an expansive and generally more potent range of activity, particularly against problematic Gram-negative bacteria. The drug is supplied as a sterile powder for injection that is reconstituted into a solution for parenteral use, administered through the Intramuscular route or Intravenous route.

Composition and the Unique Synergistic Action

The medicinal entity is typically formulated as a combination product, pairing Cefoperazone sodium with Sulbactam sodium, often in a fixed 1:1 ratio. While Cefoperazone delivers the essential therapeutic work of destroying bacteria, the inclusion of Sulbactam is a defining feature that provides differentiation. Sulbactam acts as a beta-lactamase inhibitor.

This compound prevents enzymes (beta-lactamases) produced by certain resistant bacteria from chemically destroying the Cefoperazone. This synergistic pairing maintains Cefoperazone’s activity, making the combination a reliable choice against strains that would otherwise render the antibiotic ineffective alone.

General Purpose: Targeting Systemic Bacterial Infections

The overarching purpose of this medicine is to deliver a definitive, bactericidal intervention that eradicates the living source of systemic bacterial illness. This action is achieved by Cefoperazone disrupting the final step in the synthesis of the bacterial cell wall, leading to the cell’s structural collapse and death. By actively killing the pathogens, the medicine helps resolve the infection and alleviate the acute symptoms caused by bacterial proliferation, serving as a critical agent in managing intra-abdominal or biliary tract infections.

What side effects are possible with Nextum?

Possible Side Effects and Safety Information

The official safety profile for Cefoperazone/Sulbactam (Nextum) classifies documented adverse reactions according to frequency and the body system affected, as established by regulatory documents.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on regulatory standards:

Common: Reactions observed most frequently include gastrointestinal disturbances such as diarrhea/loose stools, nausea, and vomiting.
Uncommon: Effects documented less frequently include headache, fever, chills, and localized reactions like a maculopapular rash or pain/phlebitis at the injection site.
Not Known Frequency: This classification applies to serious reactions whose incidence cannot be reliably estimated from available data, including hemorrhage (bleeding), vasculitis, and severe skin conditions like Toxic Epidermal Necrolysis (TEN).

Serious Adverse Reactions and Safety Considerations

The prescribing information highlights several reactions as clinically significant and serious:

Hypersensitivity: Severe and occasionally fatal hypersensitivity, including anaphylactic shock, is documented and represents a strict contraindication for individuals with known allergies to cephalosporins or other beta-lactam antibiotics.
Gastrointestinal Risk: The risk of Clostridium difficile-associated diarrhea (CDAD) is stated, which can occur during or even two months or more following the cessation of antibacterial treatment.
Coagulopathy: Cases of bleeding are reported, associated with hypoprothrombinemia, which may relate to factors such as poor diet or prolonged intravenous alimentation.

Safety notes for specific populations include the need for periodic organ system monitoring (renal, hepatic, and hematopoietic) during extended therapy, particularly in neonates and infants. Dosage adjustments are also required for patients with severe renal impairment to account for Sulbactam clearance, and for the Cefoperazone component in severe hepatic impairment.

Overdose and Emergency Response

Nextum Overdose and When to Seek Help

Official regulatory documents define the overdose profile of Nextum (esomeprazole) primarily through a specific set of clinical manifestations observed in cases of excessive intake.

Documented Overdose Presentations

Symptoms reported following the intake of an excessive amount of this medication include a cluster of effects impacting multiple systems. The documented manifestations are:

Central Nervous System: Confusion, drowsiness, and headache.
Visual System: Blurred vision or other vision problems.
Gastrointestinal System: Nausea and dry mouth.
Cardiovascular System: Rapid heartbeat (tachycardia).
Autonomic/Other: Sweating and flushing.

Required Emergency Actions

The most important action in an overdose situation is to seek immediate professional medical attention. The official instruction is to contact a healthcare practitioner, hospital emergency department, or a regional Poison Control Centre immediately in case of a suspected or confirmed drug overdose. This critical step must be taken even if the individual experiencing the overdose does not exhibit any symptoms at the time. Early intervention is paramount regardless of symptom severity.

Therapeutic Uses of Nextum

What Nextum Treats: Main Uses and Benefits

Targeting Severe Systemic Infections and Acute Symptoms

The combination of Cefoperazone/Sulbactam is commonly used to address conditions such as severe, acute bacterial illnesses that have become widespread throughout the body, including septicemia (blood infection) and serious lower respiratory tract infections (e.g., severe pneumonia). The medicine is applied to help address the source of the illness, and this action assists with easing symptoms related to systemic imbalance, such as debilitating high fever, persistent chills, and generalized malaise, which supports general well-being during symptomatic phases.

Treating Complicated and Deep-Seated Infections

Nextum is relevant for addressing complicated bacterial infections of the intra-abdominal space, including conditions like peritonitis, cholecystitis, cholangitis, and deep abscesses. It is also applied in managing serious infections of the skin and soft tissues, the urinary tract, and bone and joints. This combination is relevant in managing infections caused by specific multidrug-resistant (MDR) organisms that may have high resistance patterns.

“This medication is primarily relevant in clinical settings marked by heightened systemic burden, where short-term symptomatic assistance is needed.”

By focusing on the pathogens in these complex internal sites, the treatment helps to alleviate the severe localized symptoms associated with the infection, such as intense abdominal pain and acute inflammation, and contributes to improved comfort during periods of heightened symptoms. This combination is often employed when resistance is suspected or confirmed, and provides a useful approach when symptoms interfere with functional stability.

Quick Fact: Supportive Management for Systemic Discomfort The medicine assists with easing symptoms of systemic illness, providing support that helps reduce the overall burden of high fever and chills during acute infectious episodes.

Regulatory References

Philippines FDA Verification Portal product insert

Eligibility and Restrictions for Use

Eligibility Scope and Restrictions

Nextum (Cefoperazone/Sulbactam) is officially contraindicated and must not be used in patients with a documented history of hypersensitivity (allergy) to the active components, any cephalosporin, or any penicillin or beta-lactam antibiotic. This represents an absolute exclusion for these populations.

The medicine is generally approved for use in Adults, Older Adults, Children, and Infants. However, use in Premature Infants and Neonates has not been extensively studied, requiring careful assessment.

Condition-Based Eligibility Rules

Eligibility is restricted for patients with compromised organ function. Individuals with severe renal impairment (creatinine clearance less than 30 mL/min) require mandatory dose adjustment to compensate for reduced clearance of the Sulbactam component. Similarly, dose modification is required for those with severe hepatic disease or biliary obstruction due to potential accumulation of the Cefoperazone component. Close monitoring of serum concentrations is essential when both functions are impaired.

For pregnancy, use is considered only if clearly needed, given the lack of adequate and controlled studies. Caution is advised for nursing mothers. Specific regulatory warnings also identify groups with poor nutritional status or recent alcohol ingestion as populations requiring close monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interaction patterns for the Cefoperazone/Sulbactam combination, strictly based on regulatory labeling.

Drug-Substance and Timing-Based Restrictions

Cefoperazone is documented to interact with alcohol (ethanol) via a pharmacodynamic mechanism that results in a disulfiram-like reaction, leading to symptoms such as flushing and tachycardia. A mandatory timing rule requires patients to avoid alcohol during therapy and for up to 72 hours after the final dose. This restriction also applies to parenteral or oral solutions containing ethanol.

Documented Drug-Drug Interactions

Co-administration with oral anticoagulants, such as Warfarin, is associated with a risk of bleeding complications. This pharmacodynamic interaction is due to Cefoperazone's N-methylthiotetrazole (NMTT) side chain interfering with the production of Vitamin K-dependent clotting factors, thereby potentiating the effect of the anticoagulant.

Solutions of the medicine and aminoglycosides must not be directly mixed prior to administration due to documented physical incompatibility. If both are necessary, they must be administered separately. The product also has an incompatibility with initial reconstitution in Lactated Ringer’s Solution.

Population-Specific Interaction Notes

The medicine's pharmacokinetics are influenced by liver function. In patients with significant hepatic impairment, the serum half-life of Cefoperazone is prolonged. This reduced clearance increases systemic exposure, and the risk of accumulation is intensified if both hepatic and renal impairment coexist.

Mechanism of Action

Blocking the Bacterial Cell Wall Construction

Nextum's primary active ingredient, Cefoperazone, exerts its mechanism by functioning as an irreversible inhibitor of bacterial Penicillin-Binding Proteins (PBPs). PBPs are transpeptidase enzymes crucial for the final cross-linking step of the peptidoglycan layer, which provides the structural integrity of the bacterial cell wall. By chemically binding to and acylating the active site of PBPs, Cefoperazone prevents the essential cross-linking process. This inhibition leads to the structural failure of the cell wall, ultimately triggering osmotic lysis and the death of the bacterial cell.

Overcoming Bacterial Enzyme Defenses (Synergy)

To ensure the primary mechanism remains functional against resistant bacteria, the component Sulbactam acts as a suicide inhibitor against the bacterial defense mechanism, beta-Lactamase enzymes. By irreversibly inactivating beta-Lactamases, Sulbactam prevents the hydrolysis and destruction of Cefoperazone, restoring its ability to reach and inhibit PBPs. This synergistic action contributes to the reduction of the viable microbial population throughout the physiological system, thereby removing the source of the microbial burden.

Dosage and Administration Information

Instruction Map: How to use Nextum — Administration Guidelines

The use of Nextum (Cefoperazone/Sulbactam) follows an established protocol for parenteral administration, dosing, and timing. This medicine is supplied as a powder that must be reconstituted prior to use.

Category	Instruction
Route of administration	Delivered by Intravenous (IV) Infusion (administered over 15 to 60 minutes) or by Intramuscular (IM) Injection.
Standard Dosing Schedule	The standard adult regimen ranges from 2 g to 4 g of the total combination daily. The maximum daily dose for the Sulbactam component is strictly limited to 4 g.
Frequency and Timing	The total daily dose is administered in equally divided doses every 12 hours. Administration for hemodialysis patients is scheduled to occur immediately after the procedure.
Preparation Requirements	The powder must be mixed with diluents, such as 0.9% Sodium Chloride or Sterile Water. Lactated Ringer's Solution is specified as unsuitable for the initial reconstitution step.
Population-Specific Rules	Dose reductions are required for both the Cefoperazone and Sulbactam components in patients with severe hepatic or renal impairment.
Special Procedural Constraint	Patients must adhere to a procedural restriction to avoid alcohol consumption for up to 72 hours after the final dose.

Connection to the overall use protocol

The instructions establish a structured protocol that mandates precise reconstitution and administration timing, defines fixed dosage ranges and component limits, and provides rule-based adjustments necessary for use in patients with compromised hepatic or renal function, thereby standardizing its application across clinical settings.

Recent Clinical Evidence

Nextum: Recent Clinical Evidence

Phase III Clinical Trials

Studies examined a fixed-dose combination product containing two components. Research has explored whether the combination has effects on acute pain and chronic inflammation. One study evaluated whether the drug was associated with changes in quality of life measures in individuals with osteoarthritis.

Primary Endpoint: Clinical trials investigated the drug in the context of pain following surgical procedures. The clinical trials examined administration according to a predefined study protocol.
Comparison Data: One large-scale trial assessed the drug against a single-component therapy. The trial measured patient reported pain scores using a standard scale over a four-week period.

Subgroup and Safety Analyses

Studies specifically evaluated pharmacokinetics (how the body processes the drug) in elderly patients, including those with mild renal impairment. Research also examined how the body processes the drug in individuals with varying levels of hepatic function.

Drug Interactions

Researchers have examined potential interactions between the drug and alcohol consumption in controlled settings. Studies have also examined the influence of the drug on the absorption or effectiveness of co-administered treatments, such as certain anticoagulants.

Long-Term Follow-up

Long-term studies have examined whether the drug is associated with changes in inflammatory biomarkers over periods up to 12 months. Clinical investigations have explored whether the combination is associated with changes in joint function and mobility.

Based on the studies reviewed, research has evaluated the results of patient reported pain scores. Evidence from these studies can be referenced for detailed outcomes and methodological specifics.

Key Studies & References

Clinical Guideline: Pharmacological Management of Chronic Musculoskeletal Pain

Frequently Asked Questions (FAQ)

Common questions about Nextum (FAQ)

Q: How is Nextum different from other medicines used for the same issue?

Official labeling describes Nextum as a combination product that contains two components: the antibiotic Cefoperazone and Sulbactam. Sulbactam is included because it protects Cefoperazone from being destroyed by certain bacterial enzymes called beta-lactamases, which is described as maintaining the activity of the antibiotic against resistant organisms.

Q: Can Nextum be taken long-term?

Regulatory documents state that if extended therapy is necessary, a healthcare provider should periodically check certain organ system functions, specifically the renal (kidney), hepatic (liver), and hematopoietic systems. This monitoring is done to check for potential dysfunction during prolonged use.

Q: What are the most commonly mentioned side effects of Nextum online?

Based on clinical data, the most common side effect reported is diarrhea. Other commonly documented adverse effects include nausea and vomiting. Regulatory documents describe these as the most commonly reported adverse effects.

Q: Is feeling tired a common issue when starting Nextum?

Official prescribing information does not specifically list tiredness or fatigue as a common or uncommon adverse reaction. Changes in energy should be discussed with a healthcare provider.

Q: Are there serious side effects of Nextum that I should be aware of?

The official product information describes certain reactions as clinically significant. These include severe allergic responses (hypersensitivity), such as anaphylaxis, and cases of bleeding (hemorrhage), which may be related to decreased clotting factors. Severe Clostridium difficile-associated diarrhea (CDAD) is also documented as a risk.

Q: Is it true that Nextum can affect sleep?

Sleep disturbance or insomnia is not explicitly listed as an adverse reaction in the official prescribing information. The safety profile focuses primarily on gastrointestinal and hypersensitivity reactions.

Q: What kinds of non-prescription products or supplements might interact with Nextum?

The most important restriction noted in the labeling is the mandatory avoidance of alcohol (ethanol), which includes all alcoholic beverages and products containing ethanol. This is because combining it with the medicine can cause an unpleasant disulfiram-like reaction, and this restriction applies for up to 72 hours after the final dose.

Q: Can I take pain relievers like ibuprofen with Nextum?

The regulatory data advises caution when Cefoperazone is combined with other medications that can potentially increase the risk of kidney issues (nephrotoxicity). Guidance on using over-the-counter pain relievers should be obtained from a healthcare provider.

Q: Can women who are pregnant or trying to become pregnant use Nextum?

Official labeling states that this medicine should be used during pregnancy only if clearly needed due to a lack of adequate and controlled studies in pregnant women. Caution is also officially advised when the medicine is administered to a nursing mother.

Q: Is Nextum suitable for children?

The medicine is generally approved for use in adults, older adults, children, and infants. However, regulatory sources note that use in premature infants and neonates has not been extensively studied. This use requires careful risk assessment, as studies are limited.

Q: Why is Nextum sometimes used alongside other treatments?

The combination formulation (Cefoperazone and Sulbactam) is designed to ensure the antibiotic component remains active against bacteria that produce protective enzymes. Additionally, the need to use it alongside other treatments depends on the complexity of the patient's infection and overall health condition.

Q: Is Nextum a controlled substance?

No. Official classification lists Nextum (Cefoperazone/Sulbactam) as a third-generation cephalosporin antibiotic. It is not classified as a controlled substance by regulatory agencies.

Q: Is it possible to become dependent on Nextum?

The official prescribing information for this antibiotic contains no reports of dependence or abuse. This type of medication is not associated with drug dependence.

Q: Does Nextum lose effectiveness over time?

The regulatory labeling warns that during prolonged use, there is a risk of superinfection, which is the overgrowth of non-susceptible organisms. If this happens, the patient may experience symptoms that make the original therapy appear less effective.

Q: Are there any dietary restrictions associated with Nextum?

The main restriction is the mandatory avoidance of alcohol (ethanol) during and for 72 hours after therapy. The product also contains sodium, which is relevant information for patients who are on a doctor-prescribed sodium-restricted diet.

Q: What if I'm taking multiple other prescribed medications; how does that affect Nextum?

The official label specifically notes interactions with certain drug classes, such as oral anticoagulants (e.g., Warfarin) and other antibiotics like aminoglycosides. The co-administration of this medicine with other treatments is subject to professional management and monitoring.

Q: What percentage of people report experiencing a specific side effect from Nextum?

The regulatory labeling does not typically provide specific percentages of people who report side effects. Instead, it classifies them into general frequency categories such as Common, Uncommon, and Not Known Frequency.

Q: Why do some people need to adjust their dose of Nextum after a while?

Dose adjustments are required for patients who have compromised organ function, such as severe hepatic (liver) or renal (kidney) impairment. Adjustments are made to prevent the drug from accumulating in the body and potentially causing toxicity.

Q: Is Nextum prescribed for short-term problems or long-term conditions?

Official indications show Nextum is prescribed for the treatment of acute bacterial infections, such as intra-abdominal or respiratory tract infections. These types of infections typically require short-term antibiotic therapy.

Q: Can Nextum affect my ability to drive or operate machinery?

The official labeling does not include a direct warning about driving; however, side effects such as headache and fever have been reported. Patients are generally advised to note how the medicine affects them before driving or operating machinery.

Q: What is the purpose of the different strengths of Nextum tablets?

Different strengths are made available to allow a healthcare provider to administer the appropriate dosage. The dose is determined based on factors like the type and severity of the infection, as well as the patient’s individual body clearance characteristics.

Q: Does taking Nextum with food change how it works?

Official administration instructions confirm that this medicine is administered parenterally (through the intravenous (IV) or intramuscular (IM) route). Since it is an injection, the timing of food consumption does not affect its function.

Q: Does Nextum interact with herbal teas or supplements like St. John's Wort?

The official prescribing information does not specifically name St. John's Wort or other herbal teas. Official guidance often indicates that combining prescription medication with herbal or non-prescription supplements warrants discussion with a healthcare provider.

Q: If I have existing heart issues, can I still use Nextum?

The official label does not specify general heart issues as an absolute exclusion. However, the medicine contains sodium, which is a factor to consider for patients with conditions like congestive heart failure who require sodium restriction.

How should Nextum be stored and disposed of?

Storage Requirements

Nextum (Cefoperazone/Sulbactam) is supplied as a sterile powder for injection and must be stored at or below 25 C (77 F), protected from light, and kept in its original container. The powder should not be stored in environments with excessive moisture or heat.

After reconstitution into a solution, the medication has a limited shelf-life. The solution's stability is strictly time- and temperature-dependent, often requiring use within 24 hours at room temperature or up to 5 days if refrigerated (2 C–8 C). The prepared solution must be visually inspected and used only if clear and particle-free. The product must be stored out of the sight and reach of children.

Disposal Instructions

Any unused or residual portions of the reconstituted solution must be discarded immediately after the designated stability period has elapsed. As a general practice for injectable products, disposal must adhere to official pharmaceutical waste guidelines and should not be released into the environment or thrown into household trash before following proper mixing and containment procedures.

Nextum